Skip to main content

Adaptimmune Therapeutics PLC

ADAPY
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001621227

No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Adaptimmune Therapeutics PLC changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of ADAPY: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders8979−10
Shares144.7M148.3M+3.61M (+2.5%)
Value$133.9M$115.7M−$18.2M (−13.6%)

New holders (7)

Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to ADAPY in Q3 2023
InstitutionSharesValue% of portfolio
Acuitas Investments, LLC479,764$374.2K0.22%
Marquette Asset Management, LLC99,349$77.5K0.02%
Main Street Financial Solutions, LLC31,190$24.3K0.00%
Wealth Enhancement Advisory Services, LLC30,239$23.6K0.00%
ProShare Advisors LLC13,466$10.5K0.00%
Courier Capital LLC12,000$9.36K0.00%
Sandy Spring Bank1,050$8190.00%

Sold out (17)

Institutions that held Adaptimmune Therapeutics PLC at the end of Q2 2023 and filed for Q3 2023 without it.